Myovant Sciences Total Assets 2017-2022 | MYOV
Myovant Sciences total assets from 2017 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Myovant Sciences Annual Total Assets
(Millions of US $) |
| 2022 |
$520 |
| 2021 |
$725 |
| 2020 |
$106 |
| 2019 |
$173 |
| 2018 |
$119 |
| 2017 |
$185 |
| 2016 |
$0 |
Myovant Sciences Quarterly Total Assets
(Millions of US $) |
| 2022-12-31 |
$404 |
| 2022-09-30 |
$484 |
| 2022-06-30 |
$460 |
| 2022-03-31 |
$520 |
| 2021-12-31 |
$604 |
| 2021-09-30 |
$680 |
| 2021-06-30 |
$728 |
| 2021-03-31 |
$725 |
| 2020-12-31 |
$774 |
| 2020-09-30 |
$136 |
| 2020-06-30 |
$127 |
| 2020-03-31 |
$106 |
| 2019-12-31 |
$130 |
| 2019-09-30 |
$184 |
| 2019-06-30 |
$251 |
| 2019-03-31 |
$173 |
| 2018-12-31 |
$202 |
| 2018-09-30 |
$168 |
| 2018-06-30 |
$154 |
| 2018-03-31 |
$119 |
| 2017-12-31 |
$138 |
| 2017-09-30 |
$136 |
| 2017-06-30 |
$163 |
| 2017-03-31 |
$185 |
| 2016-12-31 |
$194 |
| 2016-09-30 |
$2 |
| 2016-06-30 |
$1 |
| 2016-03-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.615B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
